Isolation and characterization of degradation impurities in epirubicin hydrochloride injectionKUMAR, Dinesh; RAJESH SINGH TOMAR; SANTOSH KUMAR DEOLIA et al.Journal of chromatography. B. 2008, Vol 869, Num 1-2, pp 45-53, issn 1570-0232, 9 p.Article

Maximum a posteriori Bayesian estimation of epirubicin clearance by limited samplingRALPH, Lorraine D; THOMSON, Alison H; DOBBS, Nicola A et al.British journal of clinical pharmacology. 2004, Vol 57, Num 6, pp 764-772, issn 0306-5251, 9 p.Article

Extravasation of EpirubicinVANO-GALVAN, Sergio; JAEN, Pedro.The New England journal of medicine. 2009, Vol 360, Num 20, issn 0028-4793, p. 2117Article

Expression of CD40 has no predictive value in soft tissue sarcomasOTTAIANO, A; PISANO, C; DE CHIARA, A et al.Anticancer research. 2003, Vol 23, Num 2B, pp 1597-1604, issn 0250-7005, 8 p.Article

Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcomaPIVOT, Xavier; CHEVREAU, Christine; SAVARY, Jacqueline et al.American journal of clinical oncology. 2002, Vol 25, Num 6, pp 561-564, issn 0277-3732, 4 p.Article

Epirubicin plus docetaxel in metastatic breast cancer: Escalating dose does not improve efficacy. A phase II studyFABI, Alessandra; PAPALDO, Paola; COGNETTI, Francesco et al.Anticancer research. 2004, Vol 24, Num 3B, pp 1963-1967, issn 0250-7005, 5 p.Article

Genome-wide association study of epirubicin-induced leukopenia in Japanese patientsSRINIVASAN, Yuvaraj; SASA, Mitsunori; HONDA, Junko et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 9, pp 552-558, issn 1744-6872, 7 p.Article

In vitro and in vivo study on the antioxidant activity of dexrazoxaneGALETTA, Fabio; FRANZONI, Ferdinando; CERVETTI, Giulia et al.Biomedicine & pharmacotherapy. 2010, Vol 64, Num 4, pp 259-263, issn 0753-3322, 5 p.Article

The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancerHIRANO, Akira; SHIMIZU, Tadao; OGAWA, Kenji et al.Anticancer research. 2006, Vol 26, Num 1B, pp 581-584, issn 0250-7005, 4 p.Article

Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubblesLU, Cui-Tao; ZHAO, Ying-Zheng; YAN WU et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 2, pp 343-348, issn 0344-5704, 6 p.Article

Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivoNORRBY, Klas; NORDENHEM, Arvid.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2010, Vol 118, Num 12, pp 949-957, issn 0903-4641, 9 p.Article

Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solutionOZDEMIR, Filiz Arioz; ANILANMERT, Beril; PEKIN, Mursit et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 5, pp 529-534, issn 0344-5704, 6 p.Article

Carboplatin-epirubicin regimen for the treatment of hepatoblastomaBLOUIN, P; BRUGIERES, Laurence; TABONE, M. D et al.Pediatric blood & cancer. 2004, Vol 42, Num 2, pp 149-154, issn 1545-5009, 6 p.Article

Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicinLE, Y. L; HO, C. T; TSAI, F. L et al.European journal of pharmaceutical sciences. 2008, Vol 35, Num 1-2, pp 52-67, issn 0928-0987, 16 p.Article

Activation and relocalization of caspase 3 during the apoptotic cascade of human mesothelioma cellsSOINI, Y; KAHLOS, K; SORMUNEN, R et al.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2005, Vol 113, Num 6, pp 426-435, issn 0903-4641, 10 p.Article

Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cellsLIANG, Chia-Hua; SHIU, Li-Yen; CHANG, Li-Ching et al.Molecular nutrition & food research (Print). 2007, Vol 51, Num 8, pp 999-1005, issn 1613-4125, 7 p.Article

Factors affecting epirubicin pharmacokinetics and toxicity : Evidence against using body-surface area for dose calculationGURNEY, H. P; ACKLAND, S; GEBSKI, V et al.Journal of clinical oncology. 1998, Vol 16, Num 7, pp 2299-2304, issn 0732-183XArticle

Epirubicin Potentiates Recombinant Adeno-Associated Virus Type 2/5―Mediated TRAIL Expression in Fibroblast-like Synoviocytes and Augments the Antiarthritic Effects of rAA V2/5-TRAILJUAN SHI; ZHIJUAN DIAO; JIANSUO ZHOU et al.Arthritis and rheumatism. 2012, Vol 64, Num 5, pp 1345-1354, issn 0004-3591, 10 p.Article

What is the effect of adjusting epirubicin doses for body surface area?DOBBS, N. A; TWELVES, C. J.British journal of cancer. 1998, Vol 78, Num 5, pp 662-666, issn 0007-0920Article

Stability of intravesical epirubicin infusion: a sequential temperature studySEWELL, G. J; RIGBY-JONES, A. E; PRISTON, M. J et al.Journal of clinical pharmacy and therapeutics (Print). 2003, Vol 28, Num 5, pp 349-353, issn 0269-4727, 5 p.Article

Interaction of the anticancer drug epirubicin with DNAERDEM, Arzum; OZSOZ, Mehmet.Analytica chimica acta. 2001, Vol 437, Num 1, pp 107-114, issn 0003-2670Article

Application of preparative chromatography to the isolation of epirubicin from raw productYAN QI; JUNXIONG HUANG.Journal of liquid chromatography & related technologies. 2001, Vol 24, Num 18, pp 2837-2848, issn 1082-6076Article

Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in JapanISHIKAWA, Takashi; SHIMIZU, Satoru; OHTA, Ikuko et al.Anticancer research. 2009, Vol 29, Num 5, pp 1515-1520, issn 0250-7005, 6 p.Article

7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen speciesLO, Yu-Li; WANJEN WANG; HO, Cheng-Ta et al.Toxicology (Amsterdam). 2012, Vol 302, Num 2-3, pp 221-232, issn 0300-483X, 12 p.Article

The Pathogenetic Mechanism of Anthracycline-induced Palmar-plantar ErythrodysesthesiaMARTSCHICK, A; SEHOULI, J; PATZELT, A et al.Anticancer research. 2009, Vol 29, Num 6, pp 2307-2313, issn 0250-7005, 7 p.Article